Exscientia (Group)

https://www.exscientia.ai

Exscientia is at the forefront of Artificial Intelligence (AI)-driven drug discovery and design. By fusing the power of AI with the discovery experience of seasoned drug hunters, Exscientia is the first company to automate drug design, surpassing conventional approaches. Exscientia’s innovative Centaur Chemist™ platform enables breakthrough productivity gains as well as new approaches to improve drug efficacy. Novel compounds are automatically designed and prioritised for synthesis by its AI systems, which rapidly evolve compounds towards the desired candidate criteria for clinical development. Exscientia systems learn from both existing data resources and experimental data from each design cycle. The principle is similar to how a human would learn, but the AI process is far more effective at identifying and assimilating multiple subtle and complex trends to balance potency, selectivity and pharmacokinetic criteria. As a result, the AI-driven process is more likely to achieve the end goal and to do this more rapidly and efficiently than traditional human endeavour. Exscientia is collaborating with several leading pharmaceutical and life sciences companies, including GSK, Sanofi, Evotec, Roche and Celgene Exscientia has its headquarters in Oxford, UK with offices in the UK, USA and Japan. *

	Start	2016-04-26 existent
	Industry	drug discovery
	Industry 2	small-molecule cancer drug
	Person	Hopkins, Andrew (Ex Scientia 201604 CEO)
	Person 2	Taylor, Ben (Exscientia 202011– CFO before Aetion + Tyme Technologies + Goldman Sachs + Barclays)

	Region	Oxford, Oxfordshire
	Country	United Kingdom (GB)
	City	OX4 4GE Oxford, Oxfordshire
	Tel	+44-1865-818941
		Address record changed: 2024-03-22

Basic data	Employees	D: 101 to 500 (2023-12-31)
	Currency	GBP
	Annual sales	20,079,000 (revenue, consolidated (2023 2023-12-31)
	Profit	-145,963,000 (2023-12-31)
	Cash	363,049,000 (2023-12-31)

		* Document for »About Section«: Exscientia Ltd.. (3/22/19). "Press Release: Exscientia Continues Expansion with Establishment of a Subsidiary in Japan to Target the Pharmaceutical Market Across Asia". Oxford & Osaka.

		Record changed: 2024-03-22